-
Cubist Pharmaceuticals Inc. v. Hospira Inc. DC CAFC
- 1:12-cv-00367
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 03/21/2012
- Closed: 12/08/2014
- Latest Docket Entry: 05/24/2016
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
4
Patents-in-Suit
993
Days in
Litigation
-
Cubist Pharmaceuticals Inc. v. Hospira Inc. DC CAFC
- 1:12-cv-00367
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 03/21/2012
- Closed: 12/08/2014
- Latest Docket Entry: 05/24/2016
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 91 |
The method of claim 85 wherein the composition is daptomycin that is essentially free of each of impurities 1 to 14 defined by peaks 1-14 shown in <figref idref="DRAWINGS">FIG. 12</figref>.
|
Invalid (103)
Entry 140 Entry 135 |
| 98 |
The composition of claim 97, wherein the size selection technique is ultrafiltration or size exclusion chromatography.
|
Invalid (102 and 103)
Entry 140 Entry 135 |
| 187 |
The composition of claim 183, wherein the daptomycin composition is at least or about 97% pure.
|
Invalid (103)
Entry 140 Entry 135 |
| All Claims |
NA
|
Valid (112)
Entry 135 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 18 |
<?insert-start id="INS-S-00018" date="20060418" ?>18. An antibiotic composition comprised of a combination of a compound of formula 1, a compound of formula 2 and a compound of formula 3, or pharmaceutically acceptable salts thereof, wherein the
view more
|
Valid (112)
Entry 140 |
| 26 |
<?insert-start id="INS-S-00026" date="20060418" ?>26. A pharmaceutical formulation comprising a combination of a compound of formula 1, a compound of formula 2 and a compound of formula 3, or pharmaceutically acceptable salts thereof, wherein the
view more
|
Valid (112)
Entry 140 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 16 |
The method according to claim 14, wherein the dose is 4 mg/kg administered once every 24 hours.
|
Invalid (102 and 103)
Entry 140 Entry 135 |
| 17 |
The method according to claim 14, wherein the dose is 6 mg/kg administered once every 24 hours.
|
Invalid (102 and 103)
Entry 140 Entry 135 |
| 34 |
The method according to claim 33, wherein the dose is 4 mg/kg.
|
Invalid (102 and 103)
Entry 140 Entry 135 |
| 35 |
The method according to claim 33, wherein the dose is 6 mg/kg.
|
Invalid (102 and 103)
Entry 140 Entry 135 |
| All Claims |
NA
|
Valid (112)
Entry 135 |
-
Infringement
Hospira Incorporated
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 500mg/vial daptomycin for injectionDaptomycin for Injection 500mg/via | US 6,468,967 B1 |
16, 17, 34, 35
|
Infringement
Entry 140Entry 135 |
| 500mg/vial daptomycin for injectionDaptomycin for Injection 500mg/via | US 6,852,689 B2 |
51, 52
|
Infringement
Entry 140Entry 135 |
| 500mg/vial daptomycin for injectionDaptomycin for Injection 500mg/via | US 8,058,238 B2 |
91, 98, 187
|
Infringement
Entry 140Entry 135 |
| 500mg/vial daptomycin for injectionDaptomycin for Injection 500mg/via | US RE39,071 E1 |
18, 26
|
Infringement
Entry 140Entry 135 |
